O	0	3	Use
O	4	6	of
B-intervention	7	15	axillary
I-intervention	16	25	deodorant
O	26	29	and
O	30	36	effect
O	37	39	on
O	40	45	acute
O	46	50	skin
O	51	59	toxicity
O	60	66	during
O	67	79	radiotherapy
O	80	83	for
O	84	90	breast
O	91	97	cancer
O	97	98	:
O	99	100	a
O	101	112	prospective
O	113	123	randomized
O	124	138	noninferiority
O	139	144	trial
O	144	145	.

O	146	148	To
O	149	162	prospectively
O	163	172	determine
O	173	176	the
O	177	183	effect
O	184	186	of
O	187	196	deodorant
O	197	200	use
O	201	203	on
O	204	209	acute
O	210	214	skin
O	215	223	toxicity
O	224	227	and
O	228	235	quality
O	236	238	of
O	239	243	life
O	244	250	during
O	251	257	breast
O	258	270	radiotherapy
O	271	272	(
O	272	274	RT
O	274	275	)
O	275	276	.

O	277	283	Before
O	284	290	breast
O	291	293	RT
O	293	294	,
B-total-participants	295	297	84
O	298	306	patients
O	307	311	were
O	312	320	randomly
O	321	329	assigned
O	330	332	to
O	333	336	the
O	337	346	deodorant
O	347	352	group
O	353	354	(
O	354	355	n
O	356	357	=
B-intervention-participants	358	360	40
O	360	361	)
O	362	364	or
O	365	368	the
B-control	369	371	no
I-control	371	372	-
I-control	372	381	deodorant
O	382	387	group
O	388	389	(
O	389	390	n
O	391	392	=
B-control-participants	393	395	44
O	395	396	)
O	396	397	.

O	398	401	The
O	402	410	patients
O	411	415	were
O	416	426	stratified
O	427	429	by
O	430	438	axillary
O	439	441	RT
O	442	445	and
O	446	454	previous
O	455	467	chemotherapy
O	467	468	.

O	469	477	Toxicity
O	478	489	evaluations
O	490	494	were
O	495	501	always
O	502	511	performed
O	512	514	by
O	515	518	the
O	519	528	principal
O	529	541	investigator
O	541	542	,
O	543	546	who
O	547	550	was
O	551	558	unaware
O	559	561	of
O	562	565	the
O	566	571	group
O	572	582	assignment
O	582	583	,
O	584	586	at
O	587	590	the
O	591	594	end
O	595	597	of
O	598	600	RT
O	601	604	and
O	605	606	2
O	607	612	weeks
O	613	618	after
O	619	629	completion
O	630	635	using
O	636	639	the
O	640	649	Radiation
O	650	657	Therapy
O	658	666	Oncology
O	667	672	Group
O	673	678	acute
O	679	683	skin
O	684	692	toxicity
O	693	701	criteria
O	701	702	.

O	703	711	Symptoms
O	712	714	of
O	715	720	acute
O	721	725	skin
O	726	734	toxicity
O	735	736	(
O	736	737	i
O	737	738	.
O	739	740	e
O	740	741	.
O	741	742	,
O	743	753	discomfort
O	753	754	,
O	755	759	pain
O	759	760	,
O	761	769	pruritus
O	769	770	,
O	771	779	sweating
O	779	780	)
O	781	784	and
O	785	792	quality
O	793	795	of
O	796	800	life
O	801	805	were
O	806	810	self
O	810	811	-
O	811	820	evaluated
O	820	821	.

O	822	825	For
O	826	830	each
O	831	840	criterion
O	840	841	,
O	842	845	the
O	846	851	point
O	852	860	estimate
O	861	863	of
O	864	868	rate
O	869	879	difference
O	880	884	with
O	885	888	the
O	889	891	95
O	891	892	%
O	893	896	one
O	896	897	-
O	897	902	sided
O	903	908	upper
O	909	919	confidence
O	920	925	limit
O	926	929	was
O	930	938	computed
O	938	939	.

O	940	942	To
O	943	948	claim
O	949	963	noninferiority
O	964	969	owing
O	970	972	to
O	973	982	deodorant
O	983	986	use
O	986	987	,
O	988	991	the
O	992	994	95
O	994	995	%
O	996	999	one
O	999	1000	-
O	1000	1005	sided
O	1006	1011	upper
O	1012	1022	confidence
O	1023	1028	limit
O	1029	1032	had
O	1033	1035	to
O	1036	1038	be
O	1039	1044	lower
O	1045	1049	than
O	1050	1053	the
O	1054	1068	noninferiority
O	1069	1075	margin
O	1075	1076	,
O	1077	1082	fixed
O	1083	1085	to
O	1086	1088	12
O	1088	1089	.
O	1089	1090	8
O	1090	1091	%
O	1091	1092	.

O	1093	1095	In
O	1096	1099	the
O	1100	1109	deodorant
O	1110	1112	vs
O	1112	1113	.
O	1114	1116	no
O	1116	1117	-
O	1117	1126	deodorant
O	1127	1133	groups
O	1133	1134	,
B-outcome	1135	1140	Grade
I-outcome	1141	1142	2
I-outcome	1143	1151	axillary
I-outcome	1152	1167	radiodermatitis
O	1168	1176	occurred
O	1177	1179	in
B-iv-bin-percent	1180	1182	23
I-iv-bin-percent	1182	1183	%
O	1184	1186	vs
O	1186	1187	.
B-cv-bin-percent	1188	1190	30
I-cv-bin-percent	1190	1191	%
O	1191	1192	,
O	1193	1205	respectively
O	1205	1206	,
O	1207	1217	satisfying
O	1218	1221	the
O	1222	1233	statistical
O	1234	1242	criteria
O	1243	1246	for
O	1247	1261	noninferiority
O	1262	1263	(
O	1263	1264	p
O	1265	1266	=
O	1267	1268	.
O	1268	1271	019
O	1271	1272	)
O	1272	1273	.

B-outcome	1274	1279	Grade
I-outcome	1280	1281	2
I-outcome	1282	1288	breast
I-outcome	1289	1304	radiodermatitis
O	1305	1313	occurred
O	1314	1316	in
B-iv-bin-percent	1317	1319	30
I-iv-bin-percent	1319	1320	%
O	1321	1323	vs
O	1323	1324	.
B-cv-bin-percent	1325	1327	34
I-cv-bin-percent	1327	1328	%
O	1329	1331	of
O	1332	1335	the
O	1336	1345	deodorant
O	1346	1348	vs
O	1348	1349	.
O	1350	1352	no
O	1352	1353	-
O	1353	1362	deodorant
O	1363	1369	groups
O	1369	1370	,
O	1371	1383	respectively
O	1383	1384	,
O	1385	1389	also
O	1390	1400	satisfying
O	1401	1404	the
O	1405	1416	statistical
O	1417	1425	criteria
O	1426	1429	for
O	1430	1444	noninferiority
O	1445	1446	(
O	1446	1447	p
O	1448	1449	=
O	1450	1451	.
O	1451	1454	049
O	1454	1455	)
O	1455	1456	.

O	1457	1464	Similar
O	1465	1472	results
O	1473	1477	were
O	1478	1486	observed
O	1487	1490	for
O	1491	1494	the
O	1495	1499	self
O	1499	1500	-
O	1500	1508	reported
O	1509	1520	evaluations
O	1520	1521	.

O	1522	1525	The
O	1526	1535	deodorant
O	1536	1541	group
O	1542	1550	reported
O	1551	1555	less
B-outcome	1556	1564	sweating
O	1565	1566	(
B-iv-bin-percent	1566	1568	18
I-iv-bin-percent	1568	1569	%
O	1570	1572	vs
O	1572	1573	.
B-cv-bin-percent	1574	1576	39
I-cv-bin-percent	1576	1577	%
O	1577	1578	,
O	1579	1580	p
O	1581	1582	=
O	1583	1584	.
O	1584	1587	032
O	1587	1588	)
O	1588	1589	.

O	1590	1592	No
B-outcome	1593	1598	Grade
I-outcome	1599	1600	3
I-outcome	1601	1603	or
I-outcome	1604	1605	4
I-outcome	1606	1621	radiodermatitis
O	1622	1625	was
O	1626	1634	observed
O	1634	1635	.

O	1636	1645	According
O	1646	1648	to
O	1649	1652	our
O	1653	1667	noninferiority
O	1668	1674	margin
O	1675	1685	definition
O	1685	1686	,
O	1687	1690	the
O	1691	1701	occurrence
O	1702	1704	of
O	1705	1709	skin
O	1710	1718	toxicity
O	1719	1722	and
O	1723	1726	its
O	1727	1734	related
O	1735	1743	symptoms
O	1744	1748	were
O	1749	1762	statistically
O	1763	1773	equivalent
O	1774	1776	in
O	1777	1781	both
O	1782	1788	groups
O	1788	1789	.

O	1790	1792	No
O	1793	1801	evidence
O	1802	1805	was
O	1806	1811	found
O	1812	1814	to
O	1815	1823	prohibit
O	1824	1833	deodorant
O	1834	1837	use
O	1838	1839	(
O	1839	1854	notwithstanding
O	1855	1858	the
O	1859	1862	use
O	1863	1865	of
O	1866	1868	an
O	1869	1883	antiperspirant
O	1884	1888	with
O	1889	1897	aluminum
O	1897	1898	)
O	1899	1905	during
O	1906	1908	RT
O	1909	1912	for
O	1913	1919	breast
O	1920	1926	cancer
O	1926	1927	.
